To provide the best urological care, you need precise insights. Integrating deep genetic context with a comprehensive testing portfolio can make all the difference. Our advanced genetic tests and variety of diagnostic tools help you make more informed decisions and personalized treatment plans for your patients. Whether you're assessing prostate cancer risk or managing inherited urological conditions, we’re committed to bringing you the specific answers you need to improve health and improve lives.
Plenary session
Genetic Testing in Urologic Oncology: Now and the Future
Saturday, April 26 | 10:00 - 10:30 a.m.
Speakers:
- Prostate: Neal Shore, MD | Atlantic Urology Clinics & Carolina Urologic Research Center
- Bladder: Peter Black, MD | University of British Columbia
- Kidney: Mark Ball, MD | National Cancer Institute
Moderator:
- Adam Kibel, MD | Brigham Health and Dana-Farber Cancer Institute
There is growing evidence to support the need for expanded germline and somatic testing to treat and manage urologic cancers. This session explores the clinical utility of genetic testing for prostate, bladder and kidney cancers. In particular, the evidence for "universal" (i.e., regardless of age, stage of disease, family history or other risk factors) germline genetic testing for prostate cancer is presented, including the Invitae-led PROCLAIM trial, highlighting the utility of testing for prognostic, therapeutic and familial implications.
This session is not sponsored by Labcorp.
Click the below link to view a preview of this session.
Poster session
Abstract title: Real-World Treatment Patterns in Men with Localized Prostate Cancer Who Have Undergone Germline Genetic Testing
Saturday, April 26 | 01:00 - 03:00 p.m.
Abstract ID: 25-8278
Presenter: James Kearns, MD | Endeavor Health
This poster examines real-world treatment patterns in ~5,000 patients with localized prostate cancer who have undergone germline genetic testing. Genetic testing results and insurance claims data were matched while patterns in treatment were sorted by genetic testing result, age, race/ethnicity, family history and other factors. The most important finding is that treatment uptake varies by age and depends on genetic testing results, suggesting that genetic testing may play a role in deciding on treatments.
We will handle your contact details in line with our Privacy Policy. If you prefer not to receive marketing emails from Labcorp, you can opt-out of all marketing communications or customize your preferences here.